ММВБ 2 942 0,2%  Nasdaq 8 490 -0,4%  Биткойн 7 634 -5,7%  USD/RUB 63,7305 -0,1% 
РТС 1 454 0,4%  S&P500 3 097 -0,4%  Нефть 63,4 1,5%  EUR/RUB 70,5513 -0,2% 
Dow 27 712 -0,4%  FTSE100 7 212 -0,7%  Золото 1 469 -0,2%  EUR/USD 1,1071 0,0% 

Курс акций Biogen [ISIN: US09062X1037]

купить
продать

Biogen Inc - Профиль

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Акционеры

Название Доля (%)
Freefloat1,00
PRIMECAP Management Co.0,08
The Vanguard Group, Inc.0,07
Vanguard Group, Inc. (Subfiler)0,07
Vanguard Primecap Fund0,05
State Street Corp.0,05
ClearBridge Investments LLC0,03
BlackRock Institutional Trust Co. NA0,03
BlackRock Fund Advisors0,03
Vanguard Total Stock Market Index Fund0,03
Wellington Management Co. LLP0,02
AQR Capital Management LLC0,02
Geode Capital Management LLC0,02
Capital Research & Management Co. (World Investors)0,02
Vanguard 500 Index Fund0,02

Адрес

225 Binney Street, 02142 Cambridge
а/я:
Телефон: 1.617.679.2000
Факс:
Вэб: http://www.biogen.com

Менеджмент

Stelios B. Papadopoulos
Chairman
Robin C. Kramer
Chief Accounting Officer & Vice President
Michel Vounatsos
Chief Executive Officer & Director
Jeffrey D. Capello
Chief Financial Officer & Executive Vice President
Ginger Gregory
Chief Human Resources Officer & Executive VP
Mark Hernon
Chief Information Officer & Senior Vice President
Alfred W. Sandrock
Chief Medical Officer & EVP-Research & Development
Ed Dondero
Director-Real Estate & Planning
Alphonse Galdes
EVP-Pharmaceutical Operations & Technology
Chirfi Guindo
Executive Vice President & Head-Global Marketing
Daniel Karp
Executive Vice President-Corporate Development
Simon Nicholas Tate
Head-Covergence Development Team
Jesus B. Mantas
Independent Director
Brian S. Posner
Independent Director
Eric K. Rowinsky
Independent Director
Robert W. Pangia
Independent Director
William A. Hawkins
Independent Director
Lynn Schenk
Independent Director
Nancy L. Leaming
Independent Director
Stephen A. Sherwin
Independent Director
Caroline D. Dorsa
Independent Director
Richard Charles Mulligan
Independent Director
Alexander John Denner
Independent Director
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences
Susan H. Alexander
Secretary, Chief Legal Officer & Executive VP
Philipp Von Rosenstiel
Senior Medical Director--Alzheimers & Dementia
Wildon R. Farwell
Senior Medical Director-Clinical Development
Alisha A. Alaimo
Senior Vice President & Head-US Organization
Sanjay Jariwala
Senior Vice President & Head-Worldwide Medical
Camille Lee
Senior Vice President-Alzheimer Therapeutic Area
Anirvan Ghosh
Senior Vice President-Research & Early Development
Christopher Henderson
VP-Neurology & Movement Disorders Research Unit
Jesse M. Cedarbaum
VP-Neurology Early Clinical Development
Jacob Elkins
Vice President & Head-Acute Neurology Research
Samantha Budd Haeberlein
Vice President-Clinical Development
Richard A. Rudick
Vice President-Development Sciences

Добавить или редактировать инструмент